急性髓系白血病患者接受单倍体造血细胞移植时供者年龄的影响随预处理强度和受者年龄而异
研究纳入790例接受HLA单倍体造血细胞移植的急性髓系白血病患者,比较供者年龄≤35岁与>35岁对结局的影响。清髓性预处理组中,年长供者与慢性移植物抗宿主病及年轻受者晚期总死亡率升高相关;减低强度/非清髓性预处理组中,年长供者与非复发死亡率及年长受者晚期总死亡率升高相关。
要点
- 清髓性预处理组年长供者与慢性GVHD风险升高相关(HR 1.6)。
- 减低强度/非清髓性预处理组年长供者与非复发死亡率升高相关(HR 1.6)。
- 供者年龄选择可能需要根据受者情况制定个体化策略。
核心结论
- 供者年龄对接受单倍体造血细胞移植的急性髓系白血病患者结局的影响因预处理强度和受者年龄而异,供者选择可能需要针对特定受者制定个体化方案。
研究设计与样本
- 回顾性分析790例接受HLA单倍体造血细胞移植的急性髓系白血病患者,比较供者年龄≤35岁与>35岁对结局的影响,并校正其他非HLA和HLA因素。
主要发现
- 清髓性预处理组(n=320)中,年长供者与慢性GVHD风险显著升高相关(HR 1.6,95%CI 1.10-2.30,p=.02),对急性GVHD、复发及非复发死亡率无显著影响。
- 清髓性预处理组中,年长供者与年轻受者(≤50岁)晚期总死亡率(>6个月)显著升高相关(HR 2.2,95%CI 1.03-4.6,p=.04),年长受者中未见此关联。
- 减低强度/非清髓性预处理组(n=470)中,受者及供者年龄均不影响GVHD风险,年长供者与非复发死亡率显著升高相关(HR 1.6,95%CI 1.02-2.6,p=.04),对复发无显著影响。
- 减低强度/非清髓性预处理组中,年长供者与年长受者(>50岁)晚期总死亡率(>9个月)显著升高相关(HR 1.66,95%CI 1.0-2.67,p=.049),年轻受者中未见此关联。
临床怎么用
- 作者认为,基于供者年龄的供者选择可能需要针对特定受者制定个体化策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We investigated the impact of donor age (younger [≤35 years] vs. older [>35 years]) after accounting for other non-HLA and HLA factors on outcomes of patients with acute myeloid leukemia undergoing HLA-haploidentical hematopoietic cell transplantation (n = 790). The effect differed by conditioning-partly related to the differences in the recipient age in myeloablative (MAC; median 46 years) versus reduced-intensity/non-myeloablative conditioning (RIC/NMA; median 61 years) groups. With MAC (n = 320), donor age had no impact on acute graft-versus-host disease (GVHD), but older donors were associated with a significantly higher risk of chronic GVHD (hazard ratio [HR]: 1.6, 95% confidence interval [CI]: 1.10-2.30, p = .02) independent of recipient age and other factors. Donor age had no impact on either relapse or non-relapse mortality (NRM). The impact of donor/recipient age on overall survival changed over time. Older donors were associated with significantly higher late overall mortality (>6 months) in younger recipients (≤ 50 years; HR: 2.2, 95% CI: 1.03-4.6, p = .04) but not older recipients. With RIC/NMA (n = 470), neither recipient's nor donor's age influenced the risk of GVHD. Donor age had no significant impact on the risk of relapse, but older donors were associated with a significantly higher risk of NRM (HR: 1.6, 95% CI: 1.02-2.6, p = .04) independent of recipient age. Older donor age was associated with significantly higher late overall mortality (>9 months) in older recipients (>50 years; HR: 1.66, 95% CI: 1.0-2.67; p = .049) but not in younger recipients. Donor selection based on donor age may require a tailored approach for a particular recipient.
引用
- Saliba RM, Kanakry CG, Gadalla S, et al. Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age. Am J Hematol. 2023. PMID: 37850688. doi:10.1002/ajh.27126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。